Public company intelligence preview
VIKING THERAPEUTICS INC
55 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $5.8M average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 426 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Viking Therapeutics is a Healthcare company in the Biotechnology industry focused on developing clinical-stage therapies for metabolic and endocrine disorders. Its lead asset, VK2735, is a dual GLP-1/GIP agonist being advanced in both injectable and oral forms for obesity, with Phase 3 development underway for the subcutaneous version and positive Phase 2 oral data reported in 2025. The company also has other pipeline programs targeting MASH/NASH, lipid disorders, X-ALD, and recovery after hip fracture surgery, but it remains pre-commercial with no product revenue.
Executive Compensation Practices
For a company like Viking, executive compensation is typically driven more by clinical and regulatory milestones than by sales or earnings, since the business is still in R&D mode and has no commercial products. In this Biotechnology setting, pay packages often emphasize stock-based compensation, retention grants, and performance incentives tied to trial initiation, data readouts, partnering deals, IND/NDA progress, and capital preservation. Viking’s rapid increase in R&D spending, especially on VK2735 Phase 3 studies and manufacturing scale-up, suggests management incentives are likely aligned with advancing pipeline value and controlling development execution rather than short-term profitability.
Insider Trading Considerations
Insider trading patterns in a development-stage biotech like Viking are often highly sensitive to trial timing, topline data releases, partnership negotiations, and financing needs. Because the company’s valuation can move sharply on clinical outcomes for VK2735 and other programs, executives and directors may be subject to heightened blackout periods around major data announcements and regulatory milestones. Large cash balances help fund operations into 2027, but the company has also indicated future capital needs, so insider sales or purchases may be interpreted by the market as signals about confidence in upcoming readouts, dilution risk, or the pace of commercialization.
Unlock the full VKTX insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.